Avicenna provides feedback to the public consultation on European Medicines Agencies Network Strategy to 2025
On 4 September the Avicenna Alliance provided feedback to the public consultation on European Medicines Agencies Network Strategy to 2025!
The purpose of this public consultation was to seek views from EMA’s and HMA's stakeholders, partners and the general public on the proposed joint European Medicines Agencies Network Strategy to 2025 and whether it meets stakeholders’ needs.
The strategy will be aligned with the broader Pharmaceutical Strategy for Europe being developed by the European Commission and its actions will seek to provide synergies with actions developed under the Pharmaceutical Strategy where their subject matter overlaps.
This was a great opportunity for the Avicenna Alliance, considering that the goals and recommendations outlined in the strategy, once finalised, will inform the work of the EMA and the national competent authorities for the next five years.
We would like to thank Avicenna Members for their contributions, and more particularly, the 4 Members who have provided us with their input: Voisin Life Sciences Consulting, Dassault Systèmes, InSilicoTrials and Mediolanum Cardio Research.